Short answer
Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on June 24, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Public offering of 23,676,471 shares at $34.00 per share, including fully exercised 3,088,235-share option.
Definium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Public offering of 23,676,471 shares at $34.00 per share, including fully exercised 3,088,235-share option
- Gross proceeds approximately $805 million; net proceeds approximately $758 million after offering costs
- Proceeds funding product-candidate research, DT120 ODT commercialization preparation, working capital, and corporate purposes
- Closing expected June 25, 2026; 60-day lockup applies to directors, executives, and newly issued shares
Item 8.01 · Other Events
- Definium Therapeutics launched and priced an offering on June 22–23, 2026
- Offering details and potential shareholder impact are contained in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.2
- Proposed $500 million underwritten offering of common shares and pre-funded warrants, signaling substantial equity financing and potential dilution
- Underwriters granted 30-day option for up to $75 million of additional common shares
- Proceeds targeted to product-candidate R&D, DT120 ODT commercialization preparation, working capital, and corporate purposes
- Offering remains subject to market conditions, with final pricing, size, and terms pending
- Financing execution could extend development runway, but proceeds are not assured until closing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Definium Therapeutics, Inc. 8-K filings
Get the next DFTX 8-K as it lands
Follow DFTX for push alerts, or ask the research agent what this filing means.